ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Glenmark Pharmaceuticals released its Business Responsibility & Sustainability Report for the financial year 2025-26. This filing adheres to SEBI's regulatory disclosure requirements.
Glenmark Pharmaceuticals updated its list of key officials authorized to determine event materiality and manage stock exchange disclosures under Regulation 30(5) of SEBI LODR.
Glenmark's subsidiary announced ISB 2301, a first-in-class multispecific activator targeting solid tumors. Clinical studies are planned for 2027 following IND submission later this year.